Monoclonal Gammopathy of Undetermined Significance and Associated Clinical Risk Factors in Patients from Southern Thailand
Abstract
Objective: To assess the percentage among suspected individuals and clinical characteristics of MGUS in a Southern Thai population and examine the correlation between comorbidities and MGUS risk classifications.
Material and Methods: This retrospective cross-sectional study analyzed 1,359 patients with suspected MGUS at Songklanagarind Hospital from 2013 to 2024. Patients were stratified into risk categories based on laboratory criteria, and associations between demographic factors, comorbidities, and risk classifications were evaluated.
Results: A total of 64 MGUS cases were identified, yielding a percentage of 4.7%. IgG was the most commonly observed type of M protein (64.1%), followed by IgA (28.1%) and IgM (7.8%). MGUS was more common in males, while anemia, chronic kidney disease, and neurological disorders were less frequently observed among MGUS cases. These associations remained significant in multivariate analysis.
Conclusion: This study provides insights into the prevalence and clinical characteristics of MGUS in Southern Thailand, highlighting the impact of comorbidities on risk classifications. The findings underscore the importance of considering comorbid conditions in MGUS risk stratification beyond conventional laboratory parameters, warranting further research to refine patient care strategies.
Keywords
Full Text:
PDFReferences
Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123:78-85.
Rosiñol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc 2007;82:428-34.
Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood 2019;133:2484-94.
Abeykoon JP, Tawfiq RK, Kumar S, Ansell SM. Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond. Fac Rev 2022;11:34.
Watanaboonyongcharoen P, Nakorn TN, Rojnuckarin P, Lawasut P, Intragumtornchai T. Prevalence of monoclonal gammopathy of undetermined significance in Thailand. Int J Hematol 2012;95:176-81.
Srikummool M, Srithawong S, Muisuk K, Sangkhano S, Suwannapoom C, Kampuansai J, et al. Forensic and genetic characterizations of diverse southern Thai populations based on 15 autosomal STRs. Sci Rep 2022;12:655.
Kusolthammarat K, Yindee W, Buakaew J, Chotipanvithayakul R, Jaruthamsophon K. Human Leukocyte Antigen (HLA) Frequencies and 4-loci HLA Haplotype Frequencies in Southern Thailand. J Health Sci Med Res 2025;20251141.
Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 2010;85:933-42.
Kang KW, Song JE, Lee BH, Jeon MJ, Yu ES, Kim DS, et al. A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Sci Rep 2021;11:18449.
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American J Hematol 2022;97:1086-107.
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer 2023;152:2485-92.
Claveau JS, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J 2022;12:58.
Li Y, Bai O, Liu C, Du Z, Wang X, Wang G, et al. Association between hepatitis B virus infection and risk of multiple myeloma: a systematic review and meta-analysis. Intern Med J 2016;46:307-14.
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 2018;378:241-9.
Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85:945-8.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–7.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.